ClinicalTrials.gg
RecruitingNCT06736028KETOWEIUpdated Apr 7, 2026

Ketogenic Diets for Weight Loss Maintenance: Impact on Energy Expenditure and Appetite in Individuals With Obesity

An interventional study of Diet Therapy and Calorie Restriction in Obesity, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Obesity by University of Alabama at Birmingham — 13 open to participants now, 17 under way, 1 of them phase 3. Obesity · University of Alabama at Birmingham.

Planned enrollment
59th of 70
20 · median 56
Started
2025
with 4 others
No phase
66 of 77
10 open now
Primary completion
2026-12
later than 4 of 16 live
Registered
68th of 77
by date

Among the 77 studies in Obesity by University of Alabama at Birmingham, this one is the 59th largest by planned enrollment of the 70 interventional ones that give a count, is one of 5 that started in 2025, is one of 66 with no phase, reaches primary completion later than 4 of the 16 other live ones, and was the 68th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 77 studies in Obesity by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Obesity by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate whether a Ketogenic Diet (KD) can increase Total Energy Expenditure (TEE), while benefiting appetite, during weight loss maintenance in reduced-obese individuals.

Read the detailed description

The total duration of the intervention will be 10 weeks. Participants will first undergo 4 weeks of a low-energy diet (LED), aiming to induce a minimum of 5% weight loss (weight loss phase). Those who achieve at least a 5% weight loss will then be randomized (1:1) to a 6-week weight loss maintenance (WLM) diet, either a KD or an isocaloric low-fat diet, with the first 2 weeks being a gradual refeeding.

03

Conditions studied

  • Obesity

Keywords

  • Ketogenic Diet
  • Weight loss
  • Weight loss maintenance
  • Appetite
  • Energy expenditure
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 30-45 kg/m2
  • Both men and women
  • Age between 18-65 years
  • Sedentary to moderately active (\<2 h/wk of moderate, structured, intentional, exercise)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Daily use of tobacco (>1 pk/wk)
  • Change in weight greater than 5 lb in the previous 3 months
  • Cognitive impairment
  • Previous bariatric surgery
  • History of eating disorder
  • Presence of any condition (e.g. DM2, PCOS, inflammatory disease, untreated thyroid disease, fluid overload states such as chronic kidney disease, congestive heart failure, or cirrhosis)
  • Use of any medication (e.g., , GLP-1 analogues, hormone replacement therapy) deemed to interfere with study outcomes.
  • Pre-menopausal women will need to have a regular menstrual cycle (28+/-2 days) or be on hormonal
  • Fasting glucose plasma concentration >125 mg/dl and/or > 6.4%
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Ketogenic Diet

    Participants randomized to the ketogenic diet will follow a diet with 5% energy from carbohydrates, 70% from fat, and 25% from protein for 6 weeks. The first 2 of the 6 weeks weeks will be a gradual refeeding, with participants slowly withdrawing from the meal replacements used during the 4-week weight loss phase, while introducing more food.

    Behavioral: Diet Therapy · Behavioral: Calorie Restriction · Behavioral: Behavioral Support

  • Active comparator
    Low-Fat Diet

    Participants randomized to the low-fat diet will follow a diet with 50% energy from carbohydrates, 25% energy from fat, and 25% energy from protein for 6 weeks. The first 2 of the 6 weeks weeks will be a gradual refeeding, with participants slowly withdrawing from the meal replacements used during the 4-week weight loss phase, while introducing more food.

    Behavioral: Calorie Restriction · Behavioral: Behavioral Support · Behavioral: Diet Therapy

Interventions

  • BehavioralDiet Therapy

    Participants will be provided food to meet the ketogenic diet prescription for the 6-week weight maintenance phase.

  • BehavioralCalorie Restriction

    Participants will follow a commercial low-energy diet and be provided with meal replacements for 4 weeks aiming to achieve a minimum of 5% weight loss.

  • BehavioralBehavioral Support

    Participants will meet weekly with a registered dietitian, for a 20-minute consultation throughout the entire study period (10 weeks) to increase engagement and improve adherence and retention.

  • BehavioralDiet Therapy

    Participants will have food provided to meet the standard low-fat diet prescription for the 6-week weight maintenance phase.

06

What researchers measure

Primary outcomes

  1. Change from baseline total energy expenditure

    Total Energy Expenditure (TEE) refers to the total amount of energy (calories) your body uses in a day. Twenty-four-hour EE and RQ will be measured inside the whole room indirect calorimeter (chamber) following standard procedures

    Time frame: Baseline, week 6, week 10

Secondary outcomes

  1. Change in appetite ratings

    Subjective appetite ratings are personal feelings or perceptions about hunger, fullness, desire to eat (DTE), and prospective food consumption (PFC) usually measured using self-reported scales ranging from "not at all" to "extremely". Subjective appetite ratings (hunger, fullness, DTE and PFC) will be measured using a validated 10cm visual analog scale which will be given to the participants inside the chamber before meals.

    Time frame: Baseline, week 6, week 10

  2. Change in total body composition

    Bioimpedance analysis (BIA) will be used to measure fat mass, fat-free mass, total, extra, and intra-cellular water.

    Time frame: Baseline, week 4, week 6, week 10

  3. Change in total body composition

    FM, bone mass, and lean body mass will be determined by dual-energy X-ray absorptiometry (iDXA instrument, GE Healthcare Lunar, Madison, WI) with the use of software version 1.5g (Lunar Corp).

    Time frame: Baseline, week 4, week 6, week10

  4. Change in fasting insulin

    Circulating (serum) fasting insulin will be measured using validated methods

    Time frame: Baseline, week 6, week 10

  5. Change in fasting cholecystokinin

    Circulating (plasma) fasting cholecystokinin will be measured by RIA.

    Time frame: Baseline, week 6, week 10

  6. Change in fasting ghrelin

    Circulating (plasma) fasting ghrelin concentrations will be measured by ELISA

    Time frame: Baseline, week 6, week 10

  7. Change in fasting glucagon-like peptide-1

    Circulating (plasma) fasting total GLP-1 will be measured by ELISA

    Time frame: Baseline, week 6, week 10

  8. Change in fasting peptide YY (PYY)

    Circulating (plasma) fasting PYY3-36 concentrations will be measured by ELISA

    Time frame: Baseline, week 6, week 10

  9. Change in total body weight

    Body weight is the total amount a person weighs when measured on a scale.

    Time frame: Baseline, week 4, week 6, week 10

  10. Change in mechanical efficiency

    Walking economy will be assessed using a submaximal treadmill test, performed 90 minutes after breakfast. Following a familiarization period, participant will walk on the treadmill at 2 miles/hour for 15 minutes, followed by another 15 minutes at 2.5 miles/hour.

    Time frame: Baseline, week 6, week 10

  11. Change in resting energy expenditure

    Resting Energy Expenditure (REE) is the amount of energy (calories) your body needs to keep working while you're at rest. Participants will enter the chamber in the morning in the fasting state. REE will be measured while the participant is in the metabolic chamber.

    Time frame: Baseline, week 6, week 10

  12. Change in postprandial insulin

    Circulating (serum) insulin measured before and 30, 60, 90, and 120 minutes after intake of breakfast with validated methods

    Time frame: Baseline, week 6, week 10

  13. Change in postprandial cholecystokinin

    Circulating (plasma) cholecystokinin measured before and 30, 60, 90, and 120 minutes after intake of breakfast with RIA.

    Time frame: Baseline, week 6, week 10

  14. Change in postprandial ghrelin

    Circulating (plasma) ghrelin measured before and 30, 60, 90, and 120 minutes after intake of breakfast with ELISA

    Time frame: Baseline, week 6, week 10

  15. Change in postprandial glucagon-like peptide-1

    Circulating (plasma) total GLP-1 measured before and 30, 60, 90, and 120 minutes after intake of breakfast by ELISA

    Time frame: Baseline, week 6, week 10

  16. Change in postprandial peptide yy

    Circulating (plasma) PYY3-36 concentrations measured before and 30, 60, 90, and 120 minutes after intake of breakfast with ELISA

    Time frame: Baseline, week 6, week 10

Other outcomes

  1. Blood work: beta hydroxybutyrate

    Adherence to the dietary interventions will be assessed using objective biochemical analysis through the measurement of beta hydroxybutyrate in blood using a ketone meter.

    Time frame: Week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10

  2. Urine sample: acetoacetate

    Adherence to the dietary interventions will be assessed using objective biochemical analysis through the measurement of acetoacetate in urine using Ketostix reagent strips.

    Time frame: Week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10

  3. Change in glucose

    The fasting blood sample collected before the participants enter the chamber will be analyzed for circulating glucose using the SIRRUS analyzer.

    Time frame: Baseline, week 6, week 10

  4. Change in total cholesterol

    The fasting blood sample collected before the participants enter the chamber will be analyzed for circulating total cholesterol concentrations using the SIRRUS analyzer.

    Time frame: Baseline, week 6, week 10

  5. Change in high-density lipoprotein cholesterol

    The fasting blood sample collected before the participants enter the chamber will be analyzed for circulating HDL-C using the SIRRUS analyzer.

    Time frame: Baseline, week 6, week 10

  6. Change in triglycerides

    The fasting blood sample collected before the participants enter the chamber will be analyzed for circulating triglyceride concentrations using the SIRRUS analyzer.

    Time frame: Baseline, week 6, week 10

  7. Change in free fatty acids

    The fasting blood sample collected before the participants enter the chamber will be analyzed for circulating free fatty acid concentrations using the SIRRUS analyzer.

    Time frame: Baseline, week 6, week 10

  8. Change in average appetite

    Participants will be asked to report their average hunger, fullness, desire to eat and prospective food consumption (e.g. how hungry did you feel this week? how much did you think about food this week?) over the previous week using a 10-cm visual analogue scale ranging from "not at all" to "extremely".

    Time frame: Baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — This project will produce demographic information, anthropometric and body composition data, energy expenditure, fat oxidation, plasma concentrations of several gastrointestinal hormones involved in appetite regulation, insulin, glucose, blood lipids, and subjective appetite feelings. Data will be obtained from bioimpedance analysis and dual-energy x-ray absorptiometry (DEXA) for body compsoiiton; ELISA, RIA and other laboratorial methods used for the quantification of hormones and metabolites, and questionnaires and visual analogue scales. Data will be collected from 20 research participants. We estimate to be generating gigabyte (.csv) amounts of data. The methodology, statistical analysis plan, and a data dictionary will also be shared. Based on ethical considerations, scientific data will be de-identified and shared at the participant level. Data will be made available in .csv format and will not require the use of specialized tools to be accessed or manipulated.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The data will be shared with others by the time the related study is published and will stay available for at least 10 years.

Access criteria: All datasets that can be shared will be deposited in the NIH-supported Vivli repository which specializes in clinical trial data. Given the sensitive nature of the dataset, de-identified human subjects' data will be made available in Vivli, which restricts access to the data to qualified investigators with an appropriate research question who sign a data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 16 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 16, 2024
StartActual
Aug 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 30, 2027
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06736028
Responsible party
Catia Martins (Associate Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Dec 16, 2024
Start date
Aug 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Apr 7, 2026

Study contacts

Catia Martins, PhD
Contact
catia197@uab.edu
205-934-7922

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion